A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

This Phase 2 study tests an experimental drug called EI-1071 for people with mild to severe Alzheimer's disease. The drug targets neuroinflammation (inflammation in the brain), and researchers are evaluating its safety and whether it reduces brain inflammation as measured by PET scans. **You may be eligible if...** - You have a confirmed diagnosis of Alzheimer's disease (mild to severe) - You have measurable cognitive impairment - If you are already taking Alzheimer's medications, the dose has been stable for at least 8 weeks - Your blood counts, liver, and kidney function are adequate - You or your legal guardian can provide informed consent **You may NOT be eligible if...** - Your body weight is 150 kg or more, or your BMI is 35 or above - You have previously taken pexidartinib or other drugs targeting the same pathway within the past 3 months - You are pregnant, breastfeeding, or planning to become pregnant - You have active tuberculosis, HIV, or untreated hepatitis B or C - You have had a stroke or significant brain bleed in the past year - You have another significant neurological or psychiatric condition contributing to your cognitive decline - You are taking strong CYP3A4 inhibitors or inducers (certain medications that affect drug metabolism) Talk to your doctor to see if this trial is right for you.